Aim:A simple, accurate, precise, and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the determination of rizatriptan benzoate in oral strip formulations.Methodology:Separation was achieved under optimized chromatographic condition on a Hiper C18 column (250 mm × 4.6 mm, 5 m) using Shimadzu HPLC. The mobile phase consisted of phosphate buffer (20 mM pH adjusted to 3.2 ± 0.005 with ortho phosphoric acid): Methanol in the ratio of 70:30 v/v with isocratic elution at a flow rate of 1 ml/min at ambient temperature was performed. The detection was carried out at 225 nm using photodiode array detector. The method was validated as per Q1A (R2) guidelines and suitability of developed method was ascertained by using optimized oral strip formulation.Results:The retention time of rizatriptan benzoate was found to be 5.17 min, and the calibration curve was linear in the concentration range of 0.20-20 mg/mL (r2= 0.9998). The limit of detection and the limit of quantitation were found to be 0.016 mg/mL and 0.0528 mg/mL, respectively. Method validation parameters were found to be within the specified limits. The percentage drug content of oral strips formulation was found to be 98.96 ± 1.37.Conclusion:The proposed HPLC method may be used efficiently for routine and quality control analysis of rizatriptan benzoate in pharmaceutical formulations.
The aim of the present study is to develop Ketotifen Fumarate solid lipid nanoparticles and to evaluate them. Suitable lipids (Tristearin, GMS and Campritol), stabilizer (Soy lecithin) and surfactant (Polaxomer) were selected. FT-IR studies were carried to check drug-excipient compatibility. In the present study nine formulations were formulated by using three prepared by hot homogenization followed by ultra-sonication technique. The nanoparticles were evaluated for particle size, PDI, zeta potential Drug content, percentage drug entrapment efficiency, in vitro drug release studies, release kinetics. FT-IR drug-excipient compatibility studies were revealed that there was no interaction between drug and selected lipids. The particle size ranged from 120.4 to 359.5 nm, PDI of all formulations were good within the range of 0.410 to 0.856, zeta potential ranged from -11.25 mV to -26.5 mV, Percentage drug entrapment efficiency of all formulations were observed were in the range of 78.88 to 93.67%. The cumulative percentage release of Ketotifen Fumarate from different formulations varied from 76.61 to 93.88%. Among all formulations, the formulation F1 showed highest drug release of 93.88% and considered as optimized formulation. The release kinetic studies showed that the release was first order (R2= 0.9123) diffusion controlled and the ‘n’ value obtained from the Korsmeyer-Peppas model indicated the release mechanism was Anomalous diffusion (non-fickian type) (n-value of F1 was 0.613). The developed SLNs were able to sustain the drug release for 12hrs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.